miR-34a 和 miR-126 在非小细胞肺癌（NSCLC）肿瘤组织中的甲基化状态。
Methylation Status of miR-34a and miR-126 in Non-Small Cell Lung Cancer (NSCLC) Tumor Tissues.
机构信息
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Mesih Deneshvari Hospital Shahid Beheshti Medical Sciences University, Tehran, Iran.
出版信息
Iran Biomed J. 2024 Jan 1;28(1):53-8. doi: 10.61186/ibj.3845. Epub 2023 Oct 14.
BACKGROUND
MiR-34a and miR-126 mainly act as tumor suppressors and are often downregulated in various cancers, including non-small cell lung cancer (NSCLC). We aimed to determine the methylation status of miR-34a and miR-126 in NSCLC patients.
METHODS
The current study included 63 paraffin-embedded NSCLC and paired adjacent normal tissues. After DNA extraction and bisulfite treatment, the methylation status of miR-34a and miR-126 were evaluated using the MSP method.
RESULTS
There was no statistically significant difference between tumor and normal tissues regarding the methylation status of miR-34a and miR-126 (p > 0.05). Moreover, we found no significant correlation between the methylation status of miR-34a and miR-126 with patients’ demographic parameters, including gender, age, and pathology subtype (p > 0.05).
CONCLUSION
Considering the low expression of mir-126 and mir-34 in NSCLC, more sensitive methods are recommended to be exploited for detecting the level of methylation or underlying mechanisms other than promoter hypermethylation in silencing these genes in NSCLC.
背景
miR-34a 和 miR-126 主要作为肿瘤抑制因子，在包括非小细胞肺癌（NSCLC）在内的各种癌症中经常下调。我们旨在确定 NSCLC 患者中 miR-34a 和 miR-126 的甲基化状态。
方法
本研究包括 63 例石蜡包埋的 NSCLC 及配对的相邻正常组织。提取 DNA 并进行亚硫酸氢盐处理后，采用 MSP 法评估 miR-34a 和 miR-126 的甲基化状态。
结果
miR-34a 和 miR-126 的甲基化状态在肿瘤组织和正常组织之间无统计学差异（p>0.05）。此外，我们发现 miR-34a 和 miR-126 的甲基化状态与患者的人口统计学参数（包括性别、年龄和病理亚型）之间无显著相关性（p>0.05）。
结论
鉴于 NSCLC 中 mir-126 和 mir-34 的低表达，建议采用更敏感的方法来检测这些基因在 NSCLC 中沉默的甲基化水平或除启动子高甲基化以外的潜在机制。
Zotero 插件